Evidence map›Paper›PMID 33070257›Full record

ReviewInflammopharmacology2021

Pharmacodynamic mechanisms of anti-inflammatory drugs on the chemosensitization of multidrug-resistant cancers and the pharmacogenetics effectiveness.

Neda Gholamian Dehkordi, Seyed Abbas Mirzaei, Fatemeh Elahian

Abstract readReview
PubMed Publisher
In one paragraph

Review in Inflammopharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Enhanced Sensitivity of A549 Cells to Doxorubicin with WSInternational journal of molecular sciences · 2024
    Article
  6. Article
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Neda Gholamian DehkordiDepartment of Molecular Medicine, School of Advanced Technologies, Shahrekord University of Medical Sciences, Shahrekord, Iran.
Seyed Abbas MirzaeiCancer Research Center, Shahrekord University of Medical Sciences, Shahrekord, Iran.ORCID http://orcid.org/0000-0003-0307-3750
Fatemeh ElahianCellular and Molecular Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran. elahian@skums.ac.ir.ORCID http://orcid.org/0000-0002-1489-4047
Shahrekord University of Medical Sciences · IR

Funding

Shahrekord University of Medical Sciences SKUMS-5204
6 · The paper itself

Abstract

Drug resistance as a remarkable issue in cancer treatment is associated with inflammation which occurs through complex chemical reactions in the tumor microenvironment. Recent studies have implicated that glucocorticoids and NSAIDs are mainly useful combinations for inflammatory response modulation in chemotherapeutic protocols for cancer treatment. Immunosuppressive actions of glucocorticoids and NSAIDs are mainly mediated by the transrepression or activation regulation of inflammatory genes with different DNA-bound transcription factors including AP-1, NFAT, NF-κB, STAT and also, varying functions of COX enzymes in cancer cells. Interestingly, many investigations have proved the benefits of these anti-inflammatory agents in the quenching of multidrug resistance pathways. Numerous analyses on the ABC transporter promoters showed conserved nucleotide sequences with several DNA response elements that participate in transcriptional regulation. Furthermore, genetic variations in nucleotide sequences of membrane transporters were strongly associated with changes in these transporters' expression or function and a substantial impact on systemic drug exposure and toxicity. It appeared that several polymorphisms in MDR transporter genes especially MDR1 have influenced the regulatory mechanisms and explained differences in glucocorticoid responses.

Indexed as

AnimalsAnti-Inflammatory AgentsAntineoplastic Combined Chemotherapy ProtocolsATP-Binding Cassette TransportersDrug Resistance, MultipleDrug Resistance, NeoplasmGlucocorticoidsHumansNeoplasmsPharmacogeneticsPolymorphism, GeneticTumor MicroenvironmentAnti-Inflammatory AgentsATP-Binding Cassette TransportersGlucocorticoidsAnti-inflammatory agentsBCRPCancerGlucocorticoidsMDR1MDR promotersMRPMultidrug resistanceNSAIDPharmacogenetics

Identifiers

PMID33070257
OpenAlexW3093194818

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.